171 related articles for article (PubMed ID: 15473994)
1. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.
Grandis M; Leandri M; Vigo T; Cilli M; Sereda MW; Gherardi G; Benedetti L; Mancardi G; Abbruzzese M; Nave KA; Nobbio L; Schenone A
Exp Neurol; 2004 Nov; 190(1):213-23. PubMed ID: 15473994
[TBL] [Abstract][Full Text] [Related]
2. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
[TBL] [Abstract][Full Text] [Related]
3. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.
Hattori N; Yamamoto M; Yoshihara T; Koike H; Nakagawa M; Yoshikawa H; Ohnishi A; Hayasaka K; Onodera O; Baba M; Yasuda H; Saito T; Nakashima K; Kira J; Kaji R; Oka N; Sobue G;
Brain; 2003 Jan; 126(Pt 1):134-51. PubMed ID: 12477701
[TBL] [Abstract][Full Text] [Related]
4. Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy.
Nobbio L; Fiorese F; Vigo T; Cilli M; Gherardi G; Grandis M; Melcangi RC; Mancardi G; Abbruzzese M; Schenone A
J Neuropathol Exp Neurol; 2009 May; 68(5):441-55. PubMed ID: 19525893
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
[TBL] [Abstract][Full Text] [Related]
6. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
7. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
8. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
Meyer zu Horste G; Miesbach TA; Muller JI; Fledrich R; Stassart RM; Kieseier BC; Coleman MP; Sereda MW
Neurobiol Dis; 2011 Apr; 42(1):1-8. PubMed ID: 21168501
[TBL] [Abstract][Full Text] [Related]
9. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
10. Normal nerve striations are altered in the trembler-J mouse, a model of Charcot-Marie-Tooth disease.
Power BJ; O'reilly G; Murphy R; Murphy KJ; Pickering M; Jones JF
Muscle Nerve; 2015 Feb; 51(2):246-52. PubMed ID: 24890015
[TBL] [Abstract][Full Text] [Related]
11. Nerve conduction abnormalities in the trembler-j mouse: a model for Charcot-Marie-Tooth disease type 1A?
Meekins GD; Emery MJ; Weiss MD
J Peripher Nerv Syst; 2004 Sep; 9(3):177-82. PubMed ID: 15363066
[TBL] [Abstract][Full Text] [Related]
12. The "CMT rat": peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22.
Niemann S; Sereda MW; Rossner M; Stewart H; Suter U; Meinck HM; Griffiths IR; Nave KA
Ann N Y Acad Sci; 1999 Sep; 883():254-61. PubMed ID: 10586250
[TBL] [Abstract][Full Text] [Related]
13. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
[TBL] [Abstract][Full Text] [Related]
14. Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease.
Nobbio L; Gherardi G; Vigo T; Passalacqua M; Melloni E; Abbruzzese M; Mancardi G; Nave KA; Schenone A
Eur J Neurosci; 2006 Mar; 23(6):1445-52. PubMed ID: 16553608
[TBL] [Abstract][Full Text] [Related]
15. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
[TBL] [Abstract][Full Text] [Related]
16. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.
Kohl B; Fischer S; Groh J; Wessig C; Martini R
Am J Pathol; 2010 Mar; 176(3):1390-9. PubMed ID: 20093502
[TBL] [Abstract][Full Text] [Related]
17. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
[TBL] [Abstract][Full Text] [Related]
18. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A.
Kobsar I; Hasenpusch-Theil K; Wessig C; Müller HW; Martini R
J Neurosci Res; 2005 Sep; 81(6):857-64. PubMed ID: 16041800
[TBL] [Abstract][Full Text] [Related]
19. Nerve conduction abnormalities and neuromyotonia in genetically engineered mouse models of human hereditary neuropathies.
Zielasek J; Toyka KV
Ann N Y Acad Sci; 1999 Sep; 883():310-20. PubMed ID: 10586256
[TBL] [Abstract][Full Text] [Related]
20. A transgenic rat model of Charcot-Marie-Tooth disease.
Sereda M; Griffiths I; Pühlhofer A; Stewart H; Rossner MJ; Zimmerman F; Magyar JP; Schneider A; Hund E; Meinck HM; Suter U; Nave KA
Neuron; 1996 May; 16(5):1049-60. PubMed ID: 8630243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
